{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:48:07Z","timestamp":1787932087695,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00198-023-06732-8","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T14:03:20Z","timestamp":1680271400000},"page":"1101-1109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan"],"prefix":"10.1007","volume":"34","author":[{"given":"Takahiro","family":"Kunihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Tohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-5072","authenticated-orcid":false,"given":"Manabu","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-0350","authenticated-orcid":false,"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-5266","authenticated-orcid":false,"given":"Saeko","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"6732_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 80:920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"6732_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"key":"6732_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00198-019-04844-8","volume":"30","author":"J Tamaki","year":"2019","unstructured":"Tamaki J, Fujimori K, Ikehara S, Kamiya K, Nakatoh S, Okimoto N, Ogawa S, Ishii S, Iki M (2019) Estimates of hip fracture incidence in Japan using the national health insurance claim database in 2012\u20132015. Osteoporos Int 30:975\u2013983. https:\/\/doi.org\/10.1007\/s00198-019-04844-8","journal-title":"Osteoporos Int"},{"key":"6732_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11657-020-00797-2","volume":"15","author":"T Hamasaki","year":"2020","unstructured":"Hamasaki T, Okimoto N, Teramoto H, Shirakawa T, Nakagawa T, Mizuno N, Yamasaki T, Sasashige Y, Fujiwara S (2020) Incidence of clinical vertebral fractures and hip fractures of the elderly (65 years or over) population-large-scale data analysis using claim database in Kure City, Hiroshima. Japan Arch Osteoporos 15:124. https:\/\/doi.org\/10.1007\/s11657-020-00797-2","journal-title":"Japan Arch Osteoporos"},{"key":"6732_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7.Erratum.In:JBoneMinerMetab.2017Jan;35(1):20","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese allied committee on osteonecrosis of the jaw. J Bone Miner Metab 35:6\u201319. https:\/\/doi.org\/10.1007\/s00774-016-0810-7.Erratum.In:JBoneMinerMetab.2017Jan;35(1):20","journal-title":"J Bone Miner Metab"},{"key":"6732_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00001648-199207000-00008","volume":"3","author":"LAG Rodr\u00edguez","year":"1992","unstructured":"Rodr\u00edguez LAG, Walker AM, Gutthann SP (1992) Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 3:337\u2013342. https:\/\/doi.org\/10.1097\/00001648-199207000-00008","journal-title":"Epidemiology"},{"key":"6732_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.joms.2021.12.007","volume":"80","author":"M Ishimaru","year":"2022","unstructured":"Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H (2022) Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based study in Japan. J Oral Maxillofac Surg 80:714\u2013727. https:\/\/doi.org\/10.1016\/j.joms.2021.12.007","journal-title":"J Oral Maxillofac Surg"},{"key":"6732_CR8","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2013-4119","volume":"99","author":"WY Chiu","year":"2014","unstructured":"Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS (2014) The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab 99:2729\u20132735. https:\/\/doi.org\/10.1210\/jc.2013-4119","journal-title":"J Clin Endocrinol Metab"},{"key":"6732_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0022034510397196","volume":"90","author":"A Barasch","year":"2011","unstructured":"Barasch A, Cunha-Cruz J, Curro FA et al (2011) Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 90:439\u2013444. https:\/\/doi.org\/10.1177\/0022034510397196","journal-title":"J Dent Res"},{"key":"6732_CR10","unstructured":"Osteonecrosis of the jaw preventive care network operation manual for antiresorptive agents. http:\/\/www.kure.hiroshima.med.or.jp\/img\/file20.pdf. (in Japanese)"},{"key":"6732_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00223-015-0045-y","volume":"97","author":"A Taguchi","year":"2015","unstructured":"Taguchi A, Shiraki M, Tsukiyama M, Miyazaki T, Soen S, Ohta H, Nakamura T, Orimo H (2015) Impact of osteonecrosis of the jaw on osteoporosis treatment in Japan: results of a questionnaire-based survey by the adequate treatment of osteoporosis (A-TOP) research group. Calcif Tissue Int 97:542\u2013550. https:\/\/doi.org\/10.1007\/s00223-015-0045-y","journal-title":"Calcif Tissue Int"},{"key":"6732_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527\u2013534. https:\/\/doi.org\/10.1016\/j.joms.2004.02.004","journal-title":"J Oral Maxillofac Surg"},{"key":"6732_CR13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jcms.2016.07.026","volume":"44","author":"T M\u00fccke","year":"2016","unstructured":"M\u00fccke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, Retz M, Gschwend JE, Thalgott M (2016) Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. J Craniomaxillofac Surg 44:1689\u20131693. https:\/\/doi.org\/10.1016\/j.jcms.2016.07.026","journal-title":"J Craniomaxillofac Surg"},{"key":"6732_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145. https:\/\/doi.org\/10.1093\/annonc\/mdn526","journal-title":"Ann Oncol"},{"key":"6732_CR15","first-page":"661","volume":"83","author":"PE Petersen","year":"2005","unstructured":"Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, Ndiaye C (2005) The global burden of oral diseases and risks to oral health. Bull World Health Organ 83:661\u2013669","journal-title":"Bull World Health Organ"},{"key":"6732_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","volume":"107","author":"AD Anastasilakis","year":"2022","unstructured":"Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, Zillikens MC, Body JJ (2022) Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab 107:1441\u20131460. https:\/\/doi.org\/10.1210\/clinem\/dgab888","journal-title":"J Clin Endocrinol Metab"},{"key":"6732_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E et al (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27:383\u2013394. https:\/\/doi.org\/10.1007\/s00520-018-4501-x","journal-title":"Support Care Cancer"},{"key":"6732_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00198-014-2624-6","volume":"25","author":"TC Lin","year":"2014","unstructured":"Lin TC, Yang CY, Kao Yang YH, Lin SJ (2014) Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int 25:1503\u20131511. https:\/\/doi.org\/10.1007\/s00198-014-2624-6","journal-title":"Osteoporos Int"},{"key":"6732_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","volume":"139","author":"VM Cartsos","year":"2008","unstructured":"Cartsos VM, Zhu S, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139:23\u201330. https:\/\/doi.org\/10.14219\/jada.archive.2008.0016","journal-title":"J Am Dent Assoc"},{"key":"6732_CR20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1097\/CORR.0000000000001749","volume":"479","author":"A Bozzo","year":"2021","unstructured":"Bozzo A, Deng J, Abbas U, Bhasin R, Deodat M, Wariach S, Sanger S, Axelrod D, Masrouha K, Turcotte R, Wilson D, Ghert M (2021) Which bone-modifying agent is associated with better outcomes in patients with skeletal metastases from lung cancer? A systematic review and network meta-analysis. Clin Orthop Relat Res 479:2047\u20132057. https:\/\/doi.org\/10.1097\/CORR.0000000000001749","journal-title":"Clin Orthop Relat Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06732-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06732-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06732-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T06:07:09Z","timestamp":1684735629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06732-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6732"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06732-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent is not required for this type of study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"N. Okimoto received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd. and Teijin Pharma Ltd. N. O received payments for lectures, including speakers\u2019 bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd.; Amgen K. K.; Chugai Pharmaceutical Co.; Daiichi-Sankyo Co. Ltd.; Eli Lilly Japan.; and Teijin Pharma Ltd. S. Fujiwara received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd. T. Kunihara, H. Tohmori, M. Tsukamoto, M. Kobayashi, T. Okumura, H. Teramoto, T. Hamasaki, T. Yamasaki, and T. Nakagawa declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}